StatFinn – EPID Research: Strong and profitable growth continued in 2017


(Espoo, Finland, 19.4.2018) Contract research organization StatFinn – EPID Research reports record growth in 2017. The financial statement shows total sales of € 7,2 million (2016: 4,7 million) with a growth rate of 53,7 percent (49,2). Earnings before taxes grew to € 1,1 million (0,7).

“I am extremely pleased with our achievements in 2017. During the year, we merged StatFinn and EPID Research, while at the same time once again reached a record growth in sales and earnings. The continued trust from our clients for our services in clinical trials, Real-World Evidence and hybrid studies is a testimony to our client-oriented scientific and methodological expertise,” says Eero Mertano, CEO of StatFinn – EPID Research.

“I wish to express my strong gratitude to our personnel, whose commitment and positive attitude made this success possible. Based on our broad client-base and growing team of experts, we expect our strong global growth to continue in 2018.”


For additional information:

Eero Mertano, CEO,, +358 40 769 6275

Press release (English) | Press release (Finnish)


StatFinn and EPID present strong growth in 2016

(Espoo, Finland, 11.4.2017) StatFinn and EPID Research achieved a strong and profitable growth in 2016. Following the 2-digit growth from the previous financial year, the results show that the merged company continues the global expansion with solid basis, resources and talent. Read more details in the official press release.


StatFinn and EPID Research join forces in clinical data analytics and Real-World Evidence

(Espoo, Finland, 16.1.2017) StatFinn and EPID Research have decided to merge their operations in order to offer a full range of services to their clients in clinical data analytics and Real-World Evidence from Phase I to Phase IV and beyond. The combined company employs over 70 experts with presence in five countries: Estonia, Finland, Poland, Sweden and Switzerland. The new combination will carry on using both brands StatFinn and EPID Research.